Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 9/20 | 0.63 |
| ▸ | MMP9 | P14780 | 7/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698062 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| Benzene SCHEMBL28198278 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL698061 | 1.00 | MMP2 (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL27445164 | 0.94 | MMP2 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| D-Phenylalanine SCHEMBL8609785 | 0.91 | ALPI (0.63) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL9012465 | 0.89 | MME (0.60) | MMP2MMP9ADAMTS4MME | |
| SCHEMBL16473194 | 0.88 | MMP2 (0.50) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL16886887 | 0.87 | CYP3A4 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL16886884 | 0.87 | CYP3A4 (0.57) | MMP2MMP9ADAMTS4ALDH1A1MAPT | |
| SCHEMBL11471487 | 0.87 | POLB (0.49) | MMP2MMP9ADAMTS4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| US-5792869-A | REACTING PIPERAZINE DERIVATIVE WITH SULFONAMIDE DERIVATIVE OF OPTICALLY ACTIVE AMINO ACID, PRECIPITATING LESS SOLUBLE SALT, SEPARATING, DECOMPOSING TO DESIRED DIASTEREOMER | YAMAKAWA CHEMICAL INDUSTRY CO., LTD (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5741799-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5741792-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0832879-A1 | Process for preparing intermediates for thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0710652-B1 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL IND (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5610308-A | Process for preparing intermediates for thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0743320-A2 | Acyl guanidine and amidine prodrugs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0710652-A2 | Process for preparing optically active piperazine derivatives and intermediates for preparation | YAMAKAWA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | MMP2 879/4885MMP9 477/4885ADAMTS4 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.